TIDMRENE

RNS Number : 5214F

ReNeuron Group plc

22 March 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

Appointment of Nominated Adviser and Joint Broker

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces the appointment of Liberum Capital Limited as the Company's Nominated Adviser and Joint Broker with immediate effect.

ENDS

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Iain Ross, Chairman                                                        Via Walbrook PR 
 Catherine Isted, Chief Financial Officer 
 
 Liberum Capital Limited (NOMAD and 
  Joint Broker) 
  Phil Walker (Investment Banking) 
  Richard Lindley (Investment Banking) 
  Ben Cryer (Investment Banking)                                        +44 (0)20 3100 2000 
 
 Allenby Capital Limited (Joint Broker)                                 +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)    +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
 Paul McManus                                                           +44 (0)7980 541 893

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPGZGZFGMDGZZZ

(END) Dow Jones Newswires

March 22, 2022 03:01 ET (07:01 GMT)

Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Reneuron
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Reneuron